Such a benefit was shown for the first time in a randomized study in patients with non-small cell lung cancer (NSCLC), which demonstrated a significant increase in tumor response when an anti-PD-1 antibody was added to induction chemotherapy with cisplatin and permetrexate [18]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.